Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
JPMorgan's $500M venture capital fund dives into weight-loss craze, eyeing potential market upheaval in pharmaceuticals.
Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering first-in-class therapeuti...
Novo Nordisk is challenging Lego A/S for the title of Denmark's most valuable brand, with its brand value surging 59% to $5...
Could GLP-1 drugs for weight loss in pets be the next big thing? Success of Novo Nordisk and Eli Lilly in human market could pa...
- Bloomberg
Jim Cramer has expressed his confidence in Eli Lilly and Co, citing the company's diverse drug portfolio and the recent end...
https://www.statnews.com/2024/06/11/google-verily-glp1-weight-loss-drugs-lightpath-onduo/
